Connection

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Van Rhee, Frits

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item Type	Name
Academic Article	Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Academic Article	Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Academic Article	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Academic Article	Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Academic Article	Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Academic Article	Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Academic Article	A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Academic Article	Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
Academic Article	The molecular classification of multiple myeloma.
Academic Article	Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
Academic Article	Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Academic Article	Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Academic Article	Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
Academic Article	Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Academic Article	Turning up the heat on myeloma.
Academic Article	Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Academic Article	Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Academic Article	Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Academic Article	NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
Academic Article	A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Academic Article	Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
Academic Article	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Academic Article	Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Academic Article	First thalidomide clinical trial in multiple myeloma: a decade.
Academic Article	Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Academic Article	Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Academic Article	F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
Concept	Blood Proteins
Concept	Peripheral Blood Stem Cell Transplantation
Academic Article	Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Academic Article	Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness
Academic Article	Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Academic Article	First thalidomide clinical trial in multiple myeloma: a decade later
Academic Article	Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers
Academic Article	Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
Academic Article	Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient
Academic Article	Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse
Academic Article	Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction
Academic Article	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
Academic Article	p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias
Academic Article	Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation
Academic Article	Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
Academic Article	Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo
Academic Article	Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow
Academic Article	Total Therapy 3 (2003-33) in Gene Expression Profiling-Defined Low-Risk Multiple Myeloma Confirmed in Subsequent Trial 2006-66 with Bortezemib, Lenalidomide and Dexamethasone (VRD) Maintenance
Academic Article	Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation
Academic Article	Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance
Academic Article	HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
Academic Article	Engineering more efficacious antibody therapy for myeloma.
Academic Article	The future of autologous stem cell transplantation in myeloma.
Academic Article	CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.
Academic Article	Curing myeloma at last: defining criteria and providing the evidence.
Academic Article	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Academic Article	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Academic Article	Profile of elotuzumab and its potential in the treatment of multiple myeloma.
Academic Article	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Academic Article	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Academic Article	Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
Academic Article	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.
Academic Article	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Grant	Engraftment Kinetics of Peripheral Blood Stem Cells (PBSC's) Isolated Using the Spectra Optia Apheresis System
Grant	2004-04: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Giv
Academic Article	Storming the Castle with TCP.
Academic Article	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.
Academic Article	Long-term outcomes after autologous stem cell transplantation for multiple myeloma.
Academic Article	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
Academic Article	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
Academic Article	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
Academic Article	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Academic Article	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
Academic Article	Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
Academic Article	Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
Academic Article	Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Grant	Engraftment Kinetics of Peripheral Blood Stem Cells (PBSC's) Isolated Using the Spectra Optia Apheresis System
Academic Article	Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Academic Article	Siltuximab administration results in spurious IL-6 elevation in peripheral blood.
Academic Article	Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Academic Article	Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.
Academic Article	Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Academic Article	Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Search Criteria

Blood